Clinical Research Division, Fred Hutch
Dr. Evan Y. Yu is a medical oncologist specializing in genitourinary malignancies, specifically prostate, bladder and testicular cancer treatment and research. His research focuses on testing the next wave of novel molecular targeted therapies and immunotherapy techniques, with a complementary focus on imaging biomarkers. He is Section Head, Medical Oncology in the Clinical Research Division at Fred Hutchinson Cancer Center. He also serves as the Medical Director for Clinical Research for the Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium. He is a Professor at the University of Washington and Fred Hutchinson Cancer Center. He is principal investigator for the National Cancer Trials Network Lead Academic Performance Site (LAPS) Grant, SWOG, and ECOG/ACRIN. Dr. Yu is also the core director for the Pacific Northwest Prostate Cancer SPORE and co-PI of the DoD Prostate Cancer Clinical Trials Consortium for his institution. He graduated Alpha Omega Alpha from the University of Washington School of Medicine. Previously, he served as a Hematology/Oncology Fellowship Program Director for a decade at Fred Hutch. He has regularly been voted a “Top Doctor” by Castle Connolly, Seattle Magazine, and Seattle Met magazine. He has served for many years on the National Cancer Institute Genitourinary Cancers Steering Committee and is currently the co-chair for the National Cancer Institute Prostate Cancer Task Force. Dr. Yu has held various leadership/committee roles within ASCO, AACR, and also serves as a senior editor for Clinical Cancer Research and Uro-Today.
University of Washington School of Medicine
MD, University of Washington, 1998
BS, University of Washington, Zoology, 1994
Dr. Yu has research interests in novel PET imaging technologies in prostate cancer. Additionally, he is interested in manipulating the prostate cancer microenvironment to convert an immune exclusive microenvironment to an inflamed phenotype that will promote the utility of immunotherapy. Finally, he is doing much work in developing antibody drug conjugates for patients with bladder cancer.
Dr. Yu has research projects that span the spectrum of drug discovery and early phase testing all the way to leading large, international randomized phase 3 trials with promise to lead to new FDA approvals. For example, he is working with new immune checkpoint inhibitors that target VISTA, agents that alter the immunosuppressive microenvironment by decreasing adenosine accumulation, novel adrenal androgen annihilators and androgen receptor degraders, and also HER2 targeting in bladder cancer using antibody drug conjugates.
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email firstname.lastname@example.org or call 206.667.2210